منابع مشابه
Pharmacotherapy of smoking cessation.
Tobacco use is the number one cause of preventable diseases in the United States. Smoking accounts for more than 400,000 deaths yearly and 30% of all cancer deaths. Primary care physicians have access to 70% of smokers, approximately 60% of whom are perceived to be in excellent health. Recent advances in the pharmacotherapy of nicotine addiction, including nicotine nasal spray, nicotine inhaler...
متن کاملVarenicline: a novel pharmacotherapy for smoking cessation.
Varenicline is an orally administered small molecule with partial agonist activity at the alpha4beta2 nicotinic acetylcholine receptor. Varenicline was approved by both the US FDA and the European Medicines Agency of the EU in 2006 as an aid to smoking cessation. Subsequently, varenicline has been approved in over 80 other countries. Varenicline is almost entirely absorbed following oral admini...
متن کاملCost-effectiveness of pharmacotherapy for smoking cessation
Cost-effectiveness analysis, even with its inherent methodological problems, consistently shows that when smoking cessation interventions are effective they are invariably also cost-effective. This is largely due to their relative low cost and the big impact that stopping smoking has on health outcomes. This is also the case for pharmacotherapy for smoking cessation, including nicotine replacem...
متن کاملPharmacotherapy for smoking cessation during pregnancy.
As noted elsewhere in this issue, many pregnant women continue to smoke during pregnancy despite advice from health care providers that they should quit and/or because they have failed behavioral therapy. Continuing to smoke in the face of compelling reasons not to do so is an indication of addiction—that is, loss of control of drug use. Nicotine is responsible for addiction to cigarette smokin...
متن کاملEffectiveness of pharmacotherapy in behavioural therapeutic smoking cessation programmes.
BACKGROUND In 2011, pharmacotherapy as a part of smoking cessation treatment was reimbursed through the basic health insurance in the Netherlands. We examine the (cost)-effectiveness of pharmacotherapy added to behavioural therapy. METHODS An observational study was conducted using data from the suppliers of the smoking cessation programmes together with information on costs from health insur...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutic Advances in Cardiovascular Disease
سال: 2009
ISSN: 1753-9447,1753-9455
DOI: 10.1177/1753944709335754